Urinary Tract Infection Treatment Market Forecast to 2026 with Key Companies Profile, Supply and Growth Factors Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues. UTI infections are common health problems in females than in males with biologic factors accounting as the major cause. Antibiotics are usually the first line of treatment prescribed by doctors for urinary tract infections. According to the site of manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra), prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination, excessive and involuntary passing of urine at night are the common symptoms associated with UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI. Request PDF Brochure Of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1178 Increasing prevalence of recurring urinary infections is expected to boost growth of the urinary tract infection treatment market Rise in chronic kidney diseases and increasing use of urinary catheterization is leading to development of urinary infections and this is expected to be major growth drivers for urinary tract infection market. According to the Centers of Disease Control and Prevention, 2016, UTIs are the most common bacterial infections globally, affecting 150 million people every year. Furthermore, about 10 in 25 women and 3 in 25 men are estimated to have symptoms of at least one UTI during their lifetime. According to the study by Sultan Qaboos University Medical Journal, 2013, around 50–60% of women report at least one UTI in their lifetime, and one in three will have at least one symptomatic UTI necessitating antibiotic treatment by age 24. Also, patients with diabetes have a higher frequency of UTIs, due to the presence of long-term complications of diabetes such as neuropathy. According to the American Diabetes Association, in 2017, 9.4% of the people diagnosed with type 2 diabetes had a UTI compared to only 5.7% of people without diabetes. Approval of combination products for improving indications of existing drugs and to combat multi-drug resistant bacteria are some key factors positively affecting market growth. For instance, in 2015, FDA approved Avycaz (ceftazidime and avibactam) for complicated abdominal and urinary tract infections in combination with metronidazole that has limited or no alternative treatment options. Report includes chapters which deeply display the following deliverable about industry : • Urinary Tract Infection Treatment Market Research Objective and Assumption • Urinary Tract Infection Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Urinary Tract Infection Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Urinary Tract Infection Treatment Market, By Regions • Urinary Tract Infection Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Urinary Tract Infection Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Urinary Tract Infection Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Urinary Tract Infection Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/ buy-now/1178 Strategic collaborations is the strategy adopted by key players in the market to enhance its presence and for new drug development Strategy of leading players is to achieve growth through mergers & acquisitions and collaborations. In 2016, GlaxoSmithKline and Fimbrion Therapeutics, Inc., entered into a collaboration, which is focused on preclinical development of mannose-containing small molecule compounds called mannosides for the treatment and prevention of urinary tract infections. Key players operating in the urinary tract infection treatment market include Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, and Roche Ltd. Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/urinary-tract-infection-treatment-market1178 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues.
© Copyright 2024 Paperzz
